Delcath Systems (DCTH) Q2 2026 earnings review
Strong Execution Drives Guidance Raise as Revenue Accelerates
Delcath delivered an exceptionally strong Q2, breaking out of its recent low-$20M revenue plateau to post $29.1M (up 20% YoY). The growth was driven by a 30% YoY surge in HEPZATO volume and an expanding network of 31 active treatment centers. Most impressively, the company absorbed the 340B pricing headwinds introduced last year, with gross margins accelerating to a record 90%. While heavy R&D and commercial investments caused Adjusted EBITDA to compress YoY, the top-line momentum gave management the confidence to raise FY26 revenue guidance to $104-$108M.
🐂 Bull Case
HEPZATO volume grew 30% YoY. The CHOPIN combination data is successfully changing prescribing patterns, pushing utilization per site higher and neutralizing the threat of competitive trials.
Gross margin hit a staggering 90%, proving the company has successfully digested the 10-15% ASP discount from its entry into the 340B/Medicaid pricing program.
🐻 Bear Case
Despite a $4.9M YoY increase in gross profit, Adjusted EBITDA fell from $9.8M to $7.6M as SG&A and R&D expenses surged to fund pipeline and commercial expansion.
CHEMOSAT revenue in Europe was just $2.0M. The segment continues to limp along near breakeven, hampered by intractable reimbursement issues.
⚖️ Verdict: 🟢
Bullish. The core U.S. commercial engine for HEPZATO is firing on all cylinders. The raised guidance, record gross margins, and healthy cash balance ($95.9M) provide a massive cushion to fund the necessary pipeline expansion into larger TAMs like colorectal and breast cancer.
Key Themes
Center Activations Reversing Prior Sluggishness
After a rocky Q1 where management had to lower its FY26 active center target to 37 due to 'episodic' pacing and administrative hurdles, the network expanded successfully to 31 active centers in Q2. This steady march provides the required capacity footprint to support the raised >28% volume growth guidance.
Gross Margin Defying 340B Gravity
A year ago (Q2 25), Delcath announced entry into the NDRA/340B program, warning of a 10-15% reduction in average revenue per kit. Fast forward to today: Gross Margin has actually accelerated from 86% in 25Q2 to 90% in 26Q2. This indicates stellar manufacturing efficiency and favorable customer mix, proving management's thesis that improved Medicaid/Medicare market access would outstrip unit price concessions.
Operating Expense Surge Compressing Profits
Profitability is decelerating by design. R&D jumped 51% YoY to $10.4M, and SG&A rose 18% YoY to $13.4M. Management previously warned that R&D would surge 70-75% in 2026 to fund mCRC and mBC trials. While cash flow remains positive ($5.7M), investors must accept that near-term earnings growth will be entirely subordinated to pipeline investment.
Clinical Validation for Combination Therapies
The core product narrative is transitioning from standalone device to combination therapy platform. Independent investigators at ASCO 2026 presented data evaluating HEPZATO sequentially with tebentafusp, and in combination with nivolumab/relatlimab. Broadening the therapeutic utility to work seamlessly with modern IO and systemic therapies is critical for long-term TAM penetration.
Approaching Q3 Seasonal Headwinds
In previous years (FY25Q3 and FY26Q1 calls), management explicitly warned about Q3 summer seasonality causing a slowdown in new patient starts due to physician and patient scheduling conflicts. While the raised FY26 guidance implies they can weather it, investors should be prepared for flat or down sequential revenue in the upcoming Q3 print.
Clinical Execution Risk in Larger TAMs
The company's long-term valuation depends heavily on expanding beyond Uveal Melanoma. In Q1, management admitted enrollment in the metastatic colorectal (mCRC) trial was 'slower than initially anticipated'. While they just dosed the first patient in the mBC trial, Delcath must prove it can execute multi-site trials efficiently to hit its 2027 interim data targets.
Other KPIs
Stable and positive, though down from $7.3M in 25Q2. The ability to internally fund its aggressive R&D expansion while adding $5.7M to its $95.9M cash hoard is a massive strategic advantage over cash-burning biotech peers.
Stable but irrelevant. Up slightly from $1.7M a year ago, it represents less than 7% of total revenue. As management previously stated, Europe is managed purely on a breakeven basis for data generation, severely hampered by reimbursement limitations.
Guidance
Accelerating. Raised from the previous floor of 'at least $100M'. The $106M midpoint implies a 24% YoY growth rate compared to FY25's $85.2M. Given H1 2026 revenue of $54.1M, the company only needs ~$52M in H2 to hit the midpoint, which looks highly achievable even with Q3 seasonality.
Accelerating. The company raised the bottom end of its previous 84-87% guidance (from Q1) and blew past it by hitting 90% this quarter. This structural margin improvement dramatically lowers the breakeven threshold for the commercial business.
Accelerating. Upgraded from the previous target of >20% growth. This confirms that utilization per site (driven by CHOPIN combo data) is more than offsetting the slightly slower pace of new center activations experienced earlier in the year.
Key Questions
Margin Sustainability
Gross margin reached an impressive 90% this quarter. How much of this is structural versus a favorable quarterly mix of non-340B hospitals, and is 90% a sustainable run-rate going forward?
Navigating Q3 Seasonality
The guidance raise is highly encouraging, but Q3 has historically presented seasonal scheduling headwinds. Have you seen any changes in scheduling behavior this summer that give you confidence in a smoother Q3?
mCRC Enrollment Update
Last quarter, you noted that enrollment for the mCRC trial was slower than anticipated. With the recent launch of the mBC trial, how are you allocating clinical resources to ensure the mCRC trial stays on track for its late-2027 interim readout?